S58 - Therapeutics in Neuromuscular Disorders
Event Time: | Friday May 10, 2019 1:00 pm to 3:00 pm |
Topic(s): | Neuromuscular and Clinical Neurophysiology (EMG) |
Director(s): | |
Description: | |
Completion Message: | |
CME Credits: | 2 |
Core Competencies: |
Start/End Time | Title | Faculty |
---|---|---|
2:40 PM - 3:00 PM | Q&A Panel with Authors | Faculty |
Speaker | Disclosure |
---|
Start Time | Pub. | Title | Presenter |
---|---|---|---|
1:00 PM | 001 | Intravenous Immunoglobulin for Treatment of Demyelinating Polyneuropathy in Patients with Diabetes Mellitus: A Randomized, Double-Blinded, Placebo-Controlled Crossover Trial |
Disclosure: Dr. Breiner has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Pfizer, CSL, Allergan, Akcea. Dr. Breiner has received research support from Grifols, Inc..
|
1:00 PM | 002 | Prevalence and Associations of Peripheral Neuropathy at Disease Onset in ANCA-Associated Vasculitides: Insights from the DCVAS Study |
Disclosure: Dr. Bischof has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biogen Idec, Actelion.
|
1:00 PM | 003 | Immune-mediated rippling muscle disease, associated neoplasia and response to therapy. |
Disclosure: Dr. Triplett has nothing to disclose.
|
1:00 PM | 004 | Gene therapy after onset of neuropathy provides therapeutic benefit in a model of CMT1X |
Disclosure: Dr. Kleopa has nothing to disclose.
|
1:00 PM | 005 | RNAi/gene therapy combined approach as therapeutic strategy for Charcot-Marie-Tooth 2A |
Disclosure: Dr. Rizzo has nothing to disclose.
|
1:00 PM | 006 | Results of the Dose-Escalation Portion of a Phase 2 Study of ACE-083, a Local Muscle Therapeutic, in Patients with Charcot-Marie-Tooth (CMT) Disease |
Disclosure: Dr. Thomas has received personal compensation for consulting serving on a scientific advisory board speaking or other activities with Acceleron Genentech Novartis Pharnext Sanofi. Dr. Thomas has received personal compensation in an editorial capacity for Journal of Spinal Cord Medicine.
|
1:00 PM | 007 | Nusinersen Efficacy in Adults with Spinal Muscular Atrophy |
Disclosure: Dr. Day has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with AMO, Audentes, AveXis, Biogen, Cytokinetics, Santhera, and Sarepta. Dr. Day has received research support from AveXis, Biogen, Cytokinetics, Genzyme, Ionis, Roche, Santhera, and Sarepta.
|
1:00 PM | 008 | The Transplantation of a Specific iPSC-Derived Neural Stem Cells Subpopulation Improves the Pathological Hallmarks of Spinal Muscular Atrophy with Respiratory Distress Type 1 in Mice. |
Disclosure: Dr. Forotti has nothing to disclose.
|
1:00 PM | 009 | Kinase Inhibitors Improve Neurofilament Distribution in CMT2E Human Motor Neuron Axons |
Disclosure: Dr. Saporta has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Alnylam, Strongbridge, Biogen, Acceleron, Sarepta, Stealth, and Neurogene.
|
Ready to register for the 2019 AAN Annual Meeting?
Related Courses
9:30 AM-11:30 AM |
---|
C12 -
Clinical Approach to Muscle Disease I: Role of Antibodies, Muscle Imaging, and Genetic Testing
Tahseen Mozaffar MD, FAAN |
1:30 PM-3:30 PM |
C25 -
Clinical Approach to Muscle Disease II: Inflammatory Myopathies and Muscle Pathology
Tahseen Mozaffar MD, FAAN |
7:00 AM-9:00 AM |
---|
C46 -
Actualización en dolor de cabeza y trastornos neuromusculares (Update: Headache and Neuromuscular Disorder)
Dario Beltran MD, FAAN, Jose Merino MD, MPhil, FAAN |
C36 -
Mastering EMG Waveform Recognition Skills in Just Two Hours!
Devon Rubin MD, FAAN |
1:00 PM-3:00 PM |
C49 -
Neurology Update I: Multiple Sclerosis, Sleep, and Neuromuscular Disease
Ralph Jozefowicz MD, FAAN, Adam Quick MD |
C47 -
Evaluation and Management of Autonomic Disorders I: Autonomic Testing, Failure, and Peripheral Neuropathies
Amanda Peltier MD, MS |
S5 -
Therapeutics in ALS and SMA
|
3:30 PM-5:30 PM |
C65 -
Evaluation and Management of Autonomic Disorders II: Diagnostic Approach and Treatments for Dysautonomia
Amanda Peltier MD, MS |
11:30 AM-6:30 PM |
---|
P2 -
Poster Session 2
|
1:00 PM-3:00 PM |
C101 -
Clinical EMG I: Principles and Practice of NCS and Needle EMG
Ruple Laughlin MD, FAAN |
N2 -
Neuroscience in the Clinic: Interpretations of Genetic Results
Massimo Pandolfo MD, FAAN, Karen Marder MD, MPH, FAAN |
3:30 PM-4:45 PM |
S18 -
Autonomic Disorders
|
3:30 PM-5:30 PM |
C120 -
Clinical EMG II: Case-based Clinical Applications of Nerve Conduction Studies and Needle Electromyography
Ruple Laughlin MD, FAAN |
S23 -
Genetic Muscle Disorders
|
7:00 AM-9:00 AM |
---|
C121 -
Clinical EMG III: Nerve Conduction Criteria and Electrodiagnostic Approaches
Mark Bromberg MD, PhD, FAAN |
9:15 AM-11:30 AM |
Clinical Trials Plenary Session
Deborah Hall MD, PhD, FAAN, Holly Hinson MD, MCR, FAAN |
11:30 AM-6:30 PM |
P3 -
Poster Session 3
|
1:00 PM-3:00 PM |
C131 -
Small Fiber Neuropathies: Sensory, Autonomic, and Both I: Focus on Autonomic Nervous System
Christopher Gibbons MD, FAAN |
S25 -
Child Neurology: Spinal Muscular Atrophy: Treatments and Outcomes
|
1:00 PM-5:30 PM |
C148 -
Skills Workshop: EMG: Basic
(Registration Required)
Holli Horak MD, FAAN |
3:30 PM-5:30 PM |
C150 -
Small Fiber Neuropathies: Sensory, Autonomic, and Both II: Focus on Sensory Nervous System
Christopher Gibbons MD, FAAN |
Presentation of the Sheila Essey Award: An Award for ALS Research
|
7:00 AM-9:00 AM |
---|
C171 -
Child Neurology: Neuromuscular/Autoimmune Neurology
Anne Connolly MD, FAAN |
11:30 AM-6:30 PM |
P4 -
Poster Session 4
|
1:00 PM-3:00 PM |
C175 -
Neuromuscular Junction Disorders I: Myasthenia Gravis, Ocular, and MuSK Myasthenia
Laura Tormoehlen MD, FAAN |
N4 -
Neuroscience in the Clinic: Immunotherapies in Neurological Disease
John Corboy MD, FAAN, Holly Hinson MD, MCR, FAAN |
1:00 PM-5:30 PM |
C191 -
Skills Workshop: Neuromuscular Ultrasound
(Registration Required)
Craig Zaidman MD |
3:30 PM-5:30 PM |
C192 -
Neuromuscular Junction Disorders II: Toxins, Lambert-Eaton Syndrome and Less Common Disorders of Neuromuscular Transmission
Laura Tormoehlen MD, FAAN |
C195 -
Therapy in Neurology II: Neurocritical Care and Neuromuscular Disease
Madhu Soni MD, FAAN |
S42 -
Neuromuscular Disorders
|
7:00 AM-9:00 AM |
---|
C205 -
Peripheral Neuropathy I: Anatomical Basis and Acquired Demyelinating Neuropathies
David Herrmann MD, FAAN |
C214 -
Child Neurology: A Case-based Approach
Elaine Wirrell MD, FAAN |
11:30 AM-6:30 PM |
P5 -
Poster Session 5
|
1:00 PM-3:00 PM |
C215 -
Peripheral Neuropathy II: Update on Diabetic, Immune Axonal, and Hematologic-related Neuropathies
Michelle Mauermann MD, FAAN |
3:30 PM-5:30 PM |
C229 -
Peripheral Neuropathy III: Genetic Neuropathies: Molecular Diagnosis and Treatment Perspectives
Mario Saporta MD, PhD, FAAN |
S54 -
Motor Neuron Disease
|
7:00 PM-10:00 PM |
C237 -
Case Studies: Diagnosis and Management of Unusual Cases in Neuromuscular Disease
Robert Pascuzzi MD, FAAN |
7:00 AM-9:00 AM |
---|
C243 -
Therapy of Neuromuscular Disease: ALS, Inflammatory Neuropathies and Myopathies, and Myasthenia Gravis
Michael Weiss MD, FAAN |
9:15 AM-11:30 AM |
Neurology Year in Review Plenary Session
Martinson Arnan MD |
1:00 PM-3:00 PM |
2:00 PM-2:45 PM |
Consensus-based Care Recommendations for Adults with Myotonic Dystrophy Type 1
Nicholas Johnson MD, FAAN |
Consensus-Based Care Recommendations for Adults with haha
|